FDA approves gefurulimab (Klygefa) as first weekly self‑administered C5 inhibitor for adult gMG
The U.S. Food and Drug Administration granted approval to AstraZeneca’s Alexion unit for gefurulimab, marketed as Klygefa, to treat adults with acetylcholine‑receptor‑positive generalized myasthenia gravis. The decision is based on the phase‑3 PREVAIL trial, which showed statistically significant improvements in daily‑living and muscle‑strength scores versus placebo over 26 weeks. The drug is delivered by a weekly autoinjector and carries a boxed warning for meningococcal infection, requiring vaccination before use.
Why it matters
The approval adds a novel, self‑administered therapy to AstraZeneca’s rare‑disease portfolio, potentially expanding revenue and market share in the high‑cost specialty C5‑inhibitor segment, though pricing and launch timing have not been disclosed.
Key facts
- 1The FDA approved gefurulimab (Klygefa) on Nov 16 2026 for adults with AChR‑antibody‑positive generalized myasthenia gravis. pharmacytimes.com
- 2The PREVAIL trial enrolled 260 adults across 20 countries, with 131 receiving gefurulimab and 129 receiving placebo. pharmacytimes.com
- 3At week 26, MG‑ADL scores decreased by 4.2 points with gefurulimab versus 2.6 points with placebo (treatment difference −1.6; 95 % CI −2.4 to −0.8; P <.001). pharmacytimes.com
- 4Quantitative Myasthenia Gravis (QMG) scores fell by 4.5 points with gefurulimab versus 2.4 points with placebo (treatment difference −2.1; 95 % CI −3.1 to −1.1; P <.001). pharmacytimes.com
- 546.8 % of gefurulimab‑treated patients achieved a QMG reduction of at least 5 points, compared with 28.0 % on placebo. pharmacytimes.com
- 6Adverse events were reported in 75.6 % of the gefurulimab group and 80.6 % of the placebo group; serious adverse events occurred in 9.2 % and 11.6 % respectively. pharmacytimes.com
Open questions
- Material 1 reports injection‑site reactions in 12 % of gefurulimab patients, while material 2 reports 9.9 % (gefurulimab) and 3.1 % (placebo), creating a conflict.
- Material 1 cites an estimated 98,500 U.S. gMG patients, whereas material 2 estimates 81,000 antibody‑positive patients, a discrepancy in the patient‑population size.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.